Visualizaciones | |
---|---|
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study | 245 |
enero 2024 | febrero 2024 | marzo 2024 | abril 2024 | mayo 2024 | junio 2024 | julio 2024 | |
---|---|---|---|---|---|---|---|
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study | 0 | 0 | 199 | 11 | 12 | 16 | 7 |
Visualizaciones |
---|
Visualizaciones | |
---|---|
Estados Unidos | 201 |
China | 23 |
Holanda | 6 |
Canadá | 3 |
España | 2 |
Panamá | 1 |
Rusia | 1 |
Visualizaciones | |
---|---|
Kansas City | 134 |
Menlo Park | 16 |
Garden City | 10 |
Ann Arbor | 9 |
Houston | 8 |
Shanghai | 7 |
Guangzhou | 6 |
Oakland | 6 |
Boardman | 5 |
San Diego | 4 |